Literature DB >> 19638576

Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy.

Maria Giovanna Francipane1, Vincenzo Eterno, Valentina Spina, Miriam Bini, Gregorio Scerrino, Giuseppe Buscemi, Gaspare Gulotta, Matilde Todaro, Francesco Dieli, Ruggero De Maria, Giorgio Stassi.   

Abstract

We previously showed that cancer cells from papillary, follicular, and anaplastic thyroid carcinomas produce interleukin-4 and interleukin-10, which counteract the cytotoxic activity of conventional chemotherapy through the up-regulation of antiapoptotic molecules. Here, we identify Janus kinase/signal transducers and activators of transcription (STAT) and phosphatidyl inositol 3-kinase (PI3K)/AKT as the down-stream pathways through which these cytokines confer resistance to cell death in thyroid cancer. We found that the absence of suppressors of cytokine signaling (SOCS) molecules allows the propagation of the survival signaling. Exogenous expression of SOCS1, SOCS3, and SOCS5 in the highly aggressive anaplastic thyroid cancer cells reduces or abolishes STAT3 and 6 phosphorylation and PI3K/Akt pathway activation resulting in alteration in the balance of proapoptotic and antiapoptotic molecules and sensitization to chemotherapeutic drugs in vitro. Likewise, exogenous expression of SOCS3 significantly reduces tumor growth and potently enhances the efficacy of chemotherapy in vivo. Our results indicate that SOCS3 regulation of cytokines-prosurvival programs might represent a new strategy to overcome the resistance to chemotherapy-induced cell death of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19638576     DOI: 10.1158/0008-5472.CAN-09-0994

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues.

Authors:  Sungpil Yoon; Young-Su Yi; Sang Soo Kim; Ju-Hwa Kim; Won Sang Park; Suk Woo Nam
Journal:  Tumour Biol       Date:  2011-11-12

2.  Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma.

Authors:  Mingzhen Ying; Dawei Li; Linjun Yang; Mei Wang; Ning Wang; Ying Chen; Miaoxia He; Yajie Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-14       Impact factor: 4.553

3.  Synergistic repression of thyroid hyperplasia by cyclin C and Pten.

Authors:  Jan Jezek; Kun Wang; Ruilan Yan; Antonio Di Cristofano; Katrina F Cooper; Randy Strich
Journal:  J Cell Sci       Date:  2019-08-15       Impact factor: 5.285

4.  STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma.

Authors:  Banibrata Sen; Shaohua Peng; Denise M Woods; Ignacio Wistuba; Diana Bell; Adel K El-Naggar; Stephen Y Lai; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

Review 5.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

6.  SOCS3 blocks HIF-1α expression to inhibit proliferation and angiogenesis of human small cell lung cancer by downregulating activation of Akt, but not STAT3.

Authors:  Jun Wan; Yun Che; Ningning Kang; Wei Wu
Journal:  Mol Med Rep       Date:  2015-02-17       Impact factor: 2.952

Review 7.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

8.  Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells.

Authors:  Moon-Hong Kim; Moon-Sun Kim; Wonwoo Kim; Mi Ae Kang; Nicholas A Cacalano; Soon-Beom Kang; Young-Joo Shin; Jae-Hoon Jeong
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo.

Authors:  Christina E Arnold; Claire S Whyte; Peter Gordon; Robert N Barker; Andrew J Rees; Heather M Wilson
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

10.  Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.

Authors:  Patricia A Toniolo; Suhu Liu; Jennifer E Yeh; Darwin Q Ye; José Alexandre M Barbuto; David A Frank
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.